» Articles » PMID: 20383518

Characteristics of Multiple Sclerosis at Onset and Delay of Diagnosis and Treatment in Spain (the Novo Study)

Overview
Journal J Neurol
Specialty Neurology
Date 2010 Apr 13
PMID 20383518
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple sclerosis (MS) is a disease supposedly of autoimmune origin, with reactivity directed against myelin antigens. From the neuropathological point of view, MS produces inflammation, demyelination and axonal and neuronal degeneration. Inflammatory phenomena are predominant in the initial phase of the disease, followed later by neurodegenerative processes. Over the last decade, early treatment, during the most inflammatory phase of the disease, has been considered the best strategy to treat MS. Accordingly, we decided to determine the periods of delay between the first symptoms and the time to the first medical visit, the time to referral to a specialised MS unit, the delay in undertaking clinical and paraclinical tests, the diagnostic criteria used and the overall delay in diagnosis and treatment. The median time from onset of first symptoms to the first visit to a physician was 19.2 months, which represented the greatest delay. The median time between this initial medical consultation and the confirmation of the diagnosis by a specialised MS unit was 5.7 months, and the overall time from symptom onset to diagnosis was 24.9 months (2.08 years). The median time between onset of the first symptoms and the decision to give the first treatment was 2 years. The most important delay was that from symptom onset to the first medical visit, with the other delays being less. Thus, it is during this initial period that greater effort is required in order to reduce the time to diagnosis, by increasing awareness of the problem of MS among the general population and primary care physicians.

Citing Articles

High-Field-Blinded Assessment of Portable Ultra-Low-Field Brain MRI for Multiple Sclerosis.

Okar S, Nair G, Kawatra K, Thommana A, Donnay C, Gaitan M J Neuroimaging. 2025; 35(1):e70005.

PMID: 39815369 PMC: 11735652. DOI: 10.1111/jon.70005.


Albumin and multiple sclerosis: a prospective study from UK Biobank.

Chen K, Li C, Zhao B, Shang H Front Immunol. 2024; 15:1415160.

PMID: 38915402 PMC: 11194376. DOI: 10.3389/fimmu.2024.1415160.


Factors associated with the number of months of delaying in multiple sclerosis diagnosis: Comparison of count regression models.

Hosseinnataj A, Nikbakht R, Mousavinasab S, Eskandarieh S, Sahraian M, Baghbanian S Curr J Neurol. 2023; 22(2):65-71.

PMID: 38011390 PMC: 10460919. DOI: 10.18502/cjn.v22i2.13330.


Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences.

Uher T, Adzima A, Srpova B, Noskova L, Marechal B, Maceski A Mult Scler. 2023; 29(11-12):1437-1451.

PMID: 37840276 PMC: 10580682. DOI: 10.1177/13524585231197076.


Multiple sclerosis diagnostic delay and its associated factors in Upper Egyptian patients.

Khedr E, Malky I, Hussein H, Mahmoud D, Gamea A Sci Rep. 2023; 13(1):2249.

PMID: 36754987 PMC: 9908930. DOI: 10.1038/s41598-023-28864-x.


References
1.
Leocani L, Comi G . Neurophysiological investigations in multiple sclerosis. Curr Opin Neurol. 2000; 13(3):255-61. DOI: 10.1097/00019052-200006000-00004. View

2.
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A . Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374(9700):1503-11. DOI: 10.1016/S0140-6736(09)61259-9. View

3.
Tuohy V, Kinkel R . Epitope spreading: a mechanism for progression of autoimmune disease. Arch Immunol Ther Exp (Warsz). 2001; 48(5):347-51. View

4.
Compston A, Coles A . Multiple sclerosis. Lancet. 2008; 372(9648):1502-17. DOI: 10.1016/S0140-6736(08)61620-7. View

5.
Goodin D, Bates D . Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009; 15(10):1175-82. DOI: 10.1177/1352458509107007. View